Dr. Douglas Harrington
Join the conversations about glutathione-Interview with Dr. Douglas Harrington
Dr. Doug Harrington is a member of Max’s esteemed Medical Board and received his B.A. in Molecular Biology and M.D. from the University of Colorado. Dr. Harrington is Board Certified in Anatomic and Clinical Pathology and Hematology and has authored over 80 scientific studies and publications. He is licensed in a number of states and holds multiple professional affiliation memberships, including the American Medical Association, the American Society of Clinical Pathologists, the College of American Pathologists, the Association for Molecular Pathology and the International Academy of Pathology.
Dr. Douglas Harrington has over 25 years of experience in the research, development, commercialization, and expansion of innovative healthcare technology and services. Dr. Harrington was a member of Dr. Jack Copeland’s first heart transplant team in Arizona in 1979, and co-founded one of the first clinical molecular biology laboratories in the U.S. with the Nebraska Lymphoma Study Group headed by Dr. Jim Armitage. As former President and Lab Director of Nichols Institute, Dr. Harrington expanded their molecular genetics, infectious disease, immunology, cytogenetic, and anatomic pathology offerings. Dr. Harrington has developed patents for an automated method for image analysis of residual cancer protein, a patent covering catalytic heavy metal extraction, and a patent pending on biomarker assay for diagnosis and classification of cardiac disease. He has been involved as director or founder of multiple startup companies – from devices to molecular genetics focusing on immunology, cancer and cardiology, where he has taken a number of new molecular technologies through state and federal regulatory approval.
Throughout his career Dr. Harrington has remained a Clinical Professor of Pathology at the USC Keck School of Medicine, a published author of numerous peer-reviewed papers, and a sought-after speaker in the area of preventive medicine. In addition to being the CEO & Lab Director of Global Discovery Biosciences, Dr. Harrington is board certified in hematology, anatomic, and clinical pathology.
Dr. Harrington will share his views on why Glutathione, preventative health, and the groundbreaking new PULS test that can, along with RiboCeine, help prevent heart attacks. Learn the important, updated statistics and news about heart attacks, detection, and prevention that is vital. Reserve your Saturday morning for Dr. Harrington’s discussion.
Contact me to find how how you can listen to this recorded discussion email@example.com or (613)831-4690.